A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease

por Clark, David, Sheppard, John, Brady, Todd C.
Publicado 2021

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

por McMullin, David, Clark, David, Cavanagh, Bill, Karpecki, Paul, Brady, Todd C
Publicado 2021

Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure

por Clark, David, Karpecki, Paul, Salapatek, Anne Marie, Sheppard, John D, Brady, Todd C
Publicado 2022

Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial

por Cavanagh, Bill, Gomes, Paul J., Starr, Christopher E., Nichols, Kelly K., Brady, Todd C.
Publicado 2022

Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement

por Mandell, Kenneth J., Clark, David, Chu, David S., Foster, C. Stephen, Sheppard, John, Brady, Todd C.
Publicado 2020